Literature DB >> 23557834

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison.

Janine Dretzke1, Angela Meadows, Nicola Novielli, Aarnoud Huissoon, Anne Fry-Smith, Catherine Meads.   

Abstract

BACKGROUND: Severe allergic rhinitis uncontrolled by pharmacotherapy can adversely affect quality of life. Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have demonstrated effectiveness in this patient group; however, it remains uncertain which route of administration is more effective.
OBJECTIVES: We sought to update existing systematic reviews on the clinical effectiveness of SCIT and SLIT versus placebo, to undertake a systematic review of head-to-head trials, and to compare the relative effectiveness of SCIT and SLIT in an adjusted indirect comparison.
METHODS: Standard systematic review methods aimed at minimizing bias were used. Double-blind, randomized, placebo-controlled trials of SCIT or SLIT or trials of SCIT versus SLIT were included. Meta-analysis and indirect comparison meta-analysis with meta-regression were performed.
RESULTS: Updated meta-analyses confirmed statistically significant benefits for SCIT and SLIT compared with placebo in adults and, to a lesser extent, in children. Only 1 head-to-head trial met the inclusion criteria; both this and the indirect comparisons did not provide conclusive results in favor of either SCIT or SLIT based on symptom-medication or quality-of-life scores. There was a trend toward favoring SCIT for symptom and medication scores.
CONCLUSIONS: Although there is clear evidence of effectiveness of both SCIT and SLIT, superiority of one mode of administration over the other could not be consistently demonstrated through indirect comparison, and further research is needed to establish the comparative effectiveness of SCIT versus SLIT.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557834     DOI: 10.1016/j.jaci.2013.02.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  40 in total

Review 1.  T-cell biology in immunotherapy.

Authors:  John W Steinke; Monica G Lawrence
Journal:  Ann Allergy Asthma Immunol       Date:  2014-01-14       Impact factor: 6.347

Review 2.  Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.

Authors:  Harold S Nelson; Moises A Calderon; David I Bernstein; Thomas B Casale; Stephen R Durham; Jens S Andersen; Robert Esch; Linda S Cox; Hendrik Nolte
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

Review 3.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

Review 4.  Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

Authors:  Jasper H Kappen; Stephen R Durham; Hans In 't Veen; Mohamed H Shamji
Journal:  Ther Adv Respir Dis       Date:  2016-09-27       Impact factor: 4.031

Review 5.  Next generation immunotherapy for tree pollen allergies.

Authors:  Yan Su; Eliezer Romeu-Bonilla; Teri Heiland
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

6.  Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach.

Authors:  Ann-Kathrin Richter; Ludger Klimek; Hans F Merk; Norbert Mülleneisen; Harald Renz; Wolfgang Wehrmann; Thomas Werfel; Eckard Hamelmann; Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Janine Biermann-Stallwitz
Journal:  Eur J Health Econ       Date:  2018-03-24

7.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

8.  Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen-induced allergic rhinitis.

Authors:  S Yoshino; N Mizutani
Journal:  Br J Pharmacol       Date:  2016-04-06       Impact factor: 8.739

Review 9.  Basophils and allergic inflammation.

Authors:  Mark C Siracusa; Brian S Kim; Jonathan M Spergel; David Artis
Journal:  J Allergy Clin Immunol       Date:  2013-10       Impact factor: 10.793

Review 10.  [Costs of allergic diseases and saving potential by allergen-specific immunotherapy : A personal assessment].

Authors:  L Klimek; A M Chaker; R Mösges
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.